Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. - Wikidata - thesis-toulmin - TriplyDB

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

http://www.wikidata.org/entity/Q24815638

about

Mammalian target of rapamycin: a central node of complex signaling cascades The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials Origins, genetic landscape, and emerging therapies of small cell lung cancer Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.An integrative approach to identifying cancer chemoresistance-associated pathways NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines.Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck.Inhibitors of mTOR.Exploiting p70 S6 kinase as a target for ovarian cancer.Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.Targeting translation: eIF4E as an emerging anticancer drug target.Targeting of protein translation as a new treatment paradigm for prostate cancer.Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis.Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS).Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.

P2860

Q24601702-751DFF52-F5FE-41A4-B616-BC3EC471A61A Q26751155-E6A29E76-3B99-485E-A9AC-6C6E67FBBDAD Q26798218-2014D5D2-29E7-4910-B693-156F9B030324 Q28396304-D6EB09F9-1D2E-410A-A802-EEC32EA5CAB5 Q28474846-5521E5E5-ACC2-4D70-9461-AEDAC1F2351D Q28477202-6E64191A-C4F6-47F7-8D04-60D3ABBFAA80 Q33394687-3DE2492A-7672-4A38-9E46-9B0D12B0ED0E Q33405880-C646B181-1567-4F3D-B237-D7351D273DF4 Q33638550-8EAD56C5-2509-4F52-ADA1-BA548A2B60EF Q33853380-924EFD25-1B48-4139-BA35-771386D528EB Q34000632-60DD5B46-D416-4500-AE7E-992FE8215E99 Q34122718-67659570-D9CD-421E-B486-53AA0B6AD788 Q34141984-6DEDF612-12E1-4ECB-ABF6-81C2E4D1A452 Q34414736-1C2269DA-4008-4FA7-93A5-7BC9374EB452 Q34753639-F349822D-D6C4-41EA-92C7-9AD2DFA18D0E Q35112340-28A124FF-F306-486B-A988-DED3B513EA71 Q35487297-9776DF3F-750A-411D-AFDA-E9065F677D4D Q35670917-8A8DFF27-73C7-43C3-A35B-93C08E1FA431 Q35742521-754DDDFF-8649-4CDA-B286-382CCF86E224 Q35812082-B6C0C743-D537-4734-9C26-40ECC031BB75 Q35877999-A8550703-916D-4D74-A619-10745E445D43 Q35889790-DDF8BC68-55E0-4A68-9B74-20655DC85EC4 Q36413863-C4268512-259B-420C-BBE0-83494ACB7B59 Q36663932-151A5F93-3EF6-4ED4-919F-F49D28E4E83E Q36742629-2D6EADA8-9BEA-4B23-8230-38BE5EE04D46 Q36844334-6A0026DE-935F-455C-A880-2181EB11FE78 Q36942696-E8799E18-68F2-4B2E-9064-43F098D878D8 Q37328494-441EA958-B278-460E-A756-C68E10BFB343 Q37819463-071A1642-B386-47FF-A954-69745297B484 Q38007998-D16582CB-D8F7-44A0-A7A2-0626FC827199 Q38059212-6EE2B22A-FD87-47B8-B03E-7F62F621ACEA Q38681744-250FBED9-309D-4564-A9A3-75229AA69E20 Q38699320-485C7AF2-1B30-4C03-BEA5-799903566C19 Q39172901-33D9BAE9-47F5-44AA-9341-0366B3A6220F Q39887685-FA7E10A7-3388-4E0C-96D0-55EEFB94DC09 Q39967534-F14B934A-6938-4736-9D5D-2782095294F1 Q39970449-BC9EB4C9-CAA8-411C-B09F-E4FB8AA45B93 Q40927454-6734B7AE-A961-4A4E-AE18-8062ADD0124C Q40970978-8C12980D-7173-4EA8-B255-80C69D28EBF8 Q42494246-B295659B-314B-4592-AEEB-C105A40DFEB3

P2860

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

http://www.wikidata.org/entity/Q24815638

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

@nl

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@ast

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@en

type

label

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

@nl

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@ast

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@en

prefLabel

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer

@nl

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@ast

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@en

P1433

Q24815638-E518681C-48D3-4AED-8990-990BA15BED72

P1476

Q24815638-075B77B2-033B-4F8F-800C-31A0716E2AE8

P2093

Q24815638-03FF075C-271D-4175-BC88-A1A09CBC2C33

Q24815638-1FE0DB12-2C08-43DE-B191-9B5062999579

Q24815638-2DEAA95D-C0EC-4A09-B929-793166442748

Q24815638-36532BC2-6A62-490D-AA55-ADFF7446C11B

Q24815638-4864BC2D-7485-486B-B834-A8E015BEAB6D

Q24815638-48E09BA9-9E66-4CB5-9B0A-89E520EC21D3

Q24815638-909076D6-5FB6-4F8C-89AA-CC44153B55AE

P2860

Q24815638-02DDA067-D7FD-4660-AB1A-C2D151A6E81D

Q24815638-06204C3A-0FD7-442E-BB1B-B246C93B94C7

Q24815638-0D18A59B-0EFC-4DF2-B229-DF30CCC1F054

Q24815638-130ED606-C20E-41F0-8F27-36059E6DD46A

Q24815638-14B765F9-581E-4517-B043-B1F49B387CA3

Q24815638-1DED7311-3467-4E2F-B695-1F73CDAB96E4

Q24815638-1E5025C5-DEAC-4EBE-85CA-C985FCACB3F8

Q24815638-2B929E5A-6FB1-42DB-AFDD-BF416BB990B7

Q24815638-321F110E-57EC-4CBB-97D2-844B340A7008

Q24815638-32252667-8F6B-48CD-AD2E-4D43B77A7571

P2888

Q24815638-97A168A9-199E-4FF8-A94F-2D3EC5B7B58B

P304

Q24815638-DF7ED6E4-98D6-4B12-AABF-770E43CFB617

P31

Q24815638-C4159E78-10CE-46F7-A982-1D72B1A56B69

P356

Q24815638-735FF197-4AC7-4802-ADD9-B068F7956FC7

P407

Q24815638-AB3B6444-A186-42F6-A777-89746DD2BE59

P433

Q24815638-D2DC1E22-AF5A-4DF8-BCB1-368D19F2D330

P478

Q24815638-A283A343-26D9-47B1-BDD9-75924384197F

P577

Q24815638-D2620399-42EB-4E54-919E-908617C8641A

P5875

Q24815638-E93389C9-42B9-45B9-B512-EB8C3A067ED2

P6179

Q24815638-9540592B-2981-4E37-A0FA-C770DCA4CC92

P698

Q24815638-157F1433-6C78-4930-85E2-3E9BEF4414C2

P932

Q24815638-6A5A21F0-8C79-4281-BC77-92C2C32C9F44

P356

P1433

Molecular Cancer

P1476

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

@en

P2093

Carlos Robles

http://www.w3.org/2001/XMLSchema#string

Chunjing Wu

http://www.w3.org/2001/XMLSchema#string

Lynn Feun

http://www.w3.org/2001/XMLSchema#string

Marcus Tien Kuo

http://www.w3.org/2001/XMLSchema#string

Medhi Wangpaichitr

http://www.w3.org/2001/XMLSchema#string

Niramol Savaraj

http://www.w3.org/2001/XMLSchema#string

Theodore Lampidis

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

Rapamycins: mechanism of action and cellular resistance

Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype

The TOR pathway: a target for cancer therapy

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Regulation of translation initiation by FRAP/mTOR

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Structural, mechanistic and clinical aspects of MRP1.

P2888

P304

25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-4-25

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7710909

http://www.w3.org/2001/XMLSchema#string

P6179

1015049328

http://www.w3.org/2001/XMLSchema#string

P698

16033649

http://www.w3.org/2001/XMLSchema#string

P932

1181826

http://www.w3.org/2001/XMLSchema#string